IBAC IB Acquisition Corp.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1998781 · Fiscal year ends 09/30
Financial factors as of 2026-03-31 (2026Q2), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $624,429 | $748,177 | $180,000 | $236,772 | $172,210 | $163,485 | $176,441 | $165,458 |
| Operating income | -$624,429 | -$748,177 | -$180,000 | -$236,772 | -$172,210 | -$163,485 | -$176,441 | -$165,458 |
| Interest expense | — | — | — | — | — | — | — | -$1.52M |
| Pretax income | -$551,944 | -$611,075 | -$26,711 | $1.02M | $1.08M | $1.09M | $1.20M | $1.36M |
| Income tax | $15,222 | $28,791 | $32,191 | $151,702 | $263,382 | $262,530 | $288,021 | $320,658 |
| Net income | -$567,166 | -$639,866 | -$58,902 | $866,365 | $818,610 | $824,126 | $907,068 | $1.04M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $30,161 | $4,634 | $165,484 | $428,700 | $486,018 | $627,375 | $910,193 | $822,799 |
| Current assets | $256,535 | $288,431 | $361,778 | $1.24M | $623,225 | $864,955 | $1.17M | $1.20M |
| Total assets | $8.52M | $8.48M | $16.41M | $17.13M | $122.18M | $121.16M | $120.83M | $119.80M |
| Current liabilities | — | $1.84M | $1.16M | $1.83M | $549,009 | $355,147 | $846,324 | $722,230 |
| Total liabilities | $2.45M | $1.84M | $1.16M | $1.83M | $549,009 | $355,147 | $846,324 | $722,230 |
| Shareholders' equity | -$2.31M | -$1.69M | -$861,323 | -$681,323 | $599,661 | $771,871 | $935,356 | $1.11M |
| Shares outstanding | 4.25M | 4.25M | 4.25M | 4.25M | 4.25M | 4.25M | 4.25M | 4.25M |
| Cash flow statement | ||||||||
| Operating cash flow | -$474,473 | -$265,850 | -$1.05M | -$57,319 | -$141,357 | -$744,189 | -$375,235 | -$53,850 |
| Investing cash flow | $0 | — | — | $106.92M | $0 | $609,000 | $315,000 | $0 |
| Financing cash flow | $500,000 | — | — | — | — | — | $147,629 | $0 |
| Share buybacks | $0 | — | — | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.